We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The composite incidence of recurrent TIA and IS, acute myocardial infarction (AMI), and cardiovascular (CV) death was 4.21 and 19.2%, respectively at one and five years after the index event, an estimate unexpectedly lower than reported in the general population. Patients tended to replicate the first clinical manifestation (hazard ratio, HR: 2.41 and 4.41 for recurrent TIA and IS, respectively); additional factors for recurrent TIA were previous TIA (HR: 3.40) and microvascular disturbances (HR: 2.30); for recurrent IS arterial hypertension (HR: 4.24) and IS occurrence after MPN diagnosis (HR: 4.47). CV mortality was predicted by age over 60 years (HR: 3.98), an index IS (HR: 3.61), and the occurrence of index events after MPN diagnosis (HR: 2.62). Cytoreductive therapy was a strong protective factor (HR: 0.24). The rate of major bleeding was similar to the general population (0.90 per 100 patient-years). In conclusion, the long-term clinical outcome after TIA and IS in MPN appears even more favorable than in the general population, suggesting an advantageous benefit-risk profile of antithrombotic and cytoreductive treatment.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms / De Stefano, V; Carobbio, A; Di Lazzaro, V; Guglielmelli, P; Iurlo, A; Finazzi, Mc; Rumi, E; Cervantes, F; Elli, Em; Randi, Ml; Griesshammer, M; Palandri, F; Bonifacio, M; Hernandez-Boluda, Jc; Cacciola, R; Miroslava, P; Carli, G; Beggiato, E; Ellis, Mh; Musolino, C; Gaidano, G; Rapezzi, D; Tieghi, A; Lunghi, F; Loscocco, Gg; Cattaneo, D; Cortelezzi, A; Betti, S; Rossi, E; Finazzi, G; Censori, B; Cazzola, M; Bellini, M; Arellano-Rodrigo, E; Bertozzi, I; Sadjadian, P; Vianelli, N; Scaffidi, L; Gomez, M; Cacciola, E; Vannucchi, Am; Barbui, T. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - 8:3(2018), pp. 25-25. [10.1038/s41408-018-0048-9]

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

Carobbio A;
2018

Abstract

We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The composite incidence of recurrent TIA and IS, acute myocardial infarction (AMI), and cardiovascular (CV) death was 4.21 and 19.2%, respectively at one and five years after the index event, an estimate unexpectedly lower than reported in the general population. Patients tended to replicate the first clinical manifestation (hazard ratio, HR: 2.41 and 4.41 for recurrent TIA and IS, respectively); additional factors for recurrent TIA were previous TIA (HR: 3.40) and microvascular disturbances (HR: 2.30); for recurrent IS arterial hypertension (HR: 4.24) and IS occurrence after MPN diagnosis (HR: 4.47). CV mortality was predicted by age over 60 years (HR: 3.98), an index IS (HR: 3.61), and the occurrence of index events after MPN diagnosis (HR: 2.62). Cytoreductive therapy was a strong protective factor (HR: 0.24). The rate of major bleeding was similar to the general population (0.90 per 100 patient-years). In conclusion, the long-term clinical outcome after TIA and IS in MPN appears even more favorable than in the general population, suggesting an advantageous benefit-risk profile of antithrombotic and cytoreductive treatment.
2018
8
3
25
25
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms / De Stefano, V; Carobbio, A; Di Lazzaro, V; Guglielmelli, P; Iurlo, A; Finazzi, Mc; Rumi, E; Cervantes, F; Elli, Em; Randi, Ml; Griesshammer, M; Palandri, F; Bonifacio, M; Hernandez-Boluda, Jc; Cacciola, R; Miroslava, P; Carli, G; Beggiato, E; Ellis, Mh; Musolino, C; Gaidano, G; Rapezzi, D; Tieghi, A; Lunghi, F; Loscocco, Gg; Cattaneo, D; Cortelezzi, A; Betti, S; Rossi, E; Finazzi, G; Censori, B; Cazzola, M; Bellini, M; Arellano-Rodrigo, E; Bertozzi, I; Sadjadian, P; Vianelli, N; Scaffidi, L; Gomez, M; Cacciola, E; Vannucchi, Am; Barbui, T. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - 8:3(2018), pp. 25-25. [10.1038/s41408-018-0048-9]
De Stefano, V; Carobbio, A; Di Lazzaro, V; Guglielmelli, P; Iurlo, A; Finazzi, Mc; Rumi, E; Cervantes, F; Elli, Em; Randi, Ml; Griesshammer, M; Palandri, F; Bonifacio, M; Hernandez-Boluda, Jc; Cacciola, R; Miroslava, P; Carli, G; Beggiato, E; Ellis, Mh; Musolino, C; Gaidano, G; Rapezzi, D; Tieghi, A; Lunghi, F; Loscocco, Gg; Cattaneo, D; Cortelezzi, A; Betti, S; Rossi, E; Finazzi, G; Censori, B; Cazzola, M; Bellini, M; Arellano-Rodrigo, E; Bertozzi, I; Sadjadian, P; Vianelli, N; Scaffidi, L; Gomez, M; Cacciola, E; Vannucchi, Am; Barbui, T
File in questo prodotto:
File Dimensione Formato  
s41408-018-0048-9.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 626.88 kB
Formato Adobe PDF
626.88 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1331626
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 23
social impact